Circulating endothelial cells as biomarkers in clinical oncology.

[1]  A. Goldhirsch,et al.  Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab , 2009, Clinical Cancer Research.

[2]  E. Scott,et al.  Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. , 2009, Blood.

[3]  G. Lip,et al.  Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. , 2009, Neoplasia.

[4]  Dingcheng Gao,et al.  The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. , 2009, Trends in molecular medicine.

[5]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[6]  W. Kilarski,et al.  Biomechanical regulation of blood vessel growth during tissue vascularization , 2009, Nature Medicine.

[7]  S. Rafii,et al.  SURROGATE MARKERS PREDICT ANGIOGENIC POTENTIAL AND SURVIVAL IN PATIENTS WITH GLIOBLASTOMA MULTIFORME , 2009, Neurosurgery.

[8]  D. Jesionek-Kupnicka,et al.  Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia , 2009, Leukemia & lymphoma.

[9]  J. Heymach,et al.  Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses , 2009, Clinical Cancer Research.

[10]  A. Goldhirsch,et al.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[12]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[13]  S. Rafii,et al.  A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization. , 2008, Cancer cell.

[14]  M. Cazzola,et al.  Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes , 2008, Leukemia.

[15]  S. Barsky,et al.  Precancerous Stem Cells Can Serve As Tumor Vasculogenic Progenitors , 2008, PloS one.

[16]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[17]  M. Brittan,et al.  CD133: molecule of the moment , 2008, The Journal of pathology.

[18]  P. Smolewski,et al.  Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients , 2008, Annals of Hematology.

[19]  R. Kerbel,et al.  Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation , 2007, PloS one.

[20]  Kenneth P. Roos,et al.  Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.

[21]  J. Soria,et al.  Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Yoder,et al.  Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. , 2007, Experimental hematology.

[23]  D. Scheinberg,et al.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. , 2007, Genes & development.

[24]  S. Seaman,et al.  Genes that distinguish physiological and pathological angiogenesis. , 2007, Cancer cell.

[25]  J. Manola,et al.  Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor , 2007, Clinical Cancer Research.

[26]  S. Dias,et al.  Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. , 2007, Haematologica.

[27]  J. Prchal,et al.  Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. , 2007, Blood.

[28]  S. Rafii,et al.  Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer , 2007, Breast Cancer Research and Treatment.

[29]  Robert S. Kerbel,et al.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification , 2006, Nature Reviews Cancer.

[30]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[31]  A. Goldhirsch,et al.  Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. , 2006, Blood.

[32]  E. Raso,et al.  Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. , 2006, Cancer research.

[33]  K. Gatter,et al.  Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions , 2006, British Journal of Cancer.

[34]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[35]  R. Kerbel,et al.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. , 2005, Blood.

[36]  A. Rosenzweig.  Circulating endothelial progenitors--cells as biomarkers. , 2005, The New England journal of medicine.

[37]  B. Peters,et al.  Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.

[38]  Françoise Dignat-George,et al.  Circulating endothelial cells , 2005, Thrombosis and Haemostasis.

[39]  P. Carmeliet,et al.  A surrogate marker to monitor angiogenesis at last. , 2005, Cancer cell.

[40]  R. D'Amato,et al.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.

[41]  G. Veronesi,et al.  Assessing Tumor Angiogenesis , 2004, Cancer Research.

[42]  Raghu Kalluri,et al.  Cancer without disease , 2004, Nature.

[43]  W. Gerald,et al.  Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.

[44]  E. Gunsilius.  Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. , 2003, Advances in experimental medicine and biology.

[45]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[46]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[47]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[48]  G. Pruneri,et al.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.

[49]  A. Goldhirsch,et al.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.

[50]  S. Dirnhofer,et al.  Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells , 2000, The Lancet.

[51]  S. Rafii,et al.  Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. , 2000, Blood.

[52]  S. Rafii,et al.  Evidence for circulating bone marrow-derived endothelial cells. , 1998, Blood.

[53]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[54]  N. Simionescu,et al.  Binding of vascular anticoagulant alpha (annexin V) to the aortic intima of the hypercholesterolemic rabbit. An autoradiographic study , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[55]  R. Kerbel,et al.  Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[56]  P. Rossmann,et al.  Circulating endothelial cells isolated together with platelets and the experimental modification of their counts in rats , 1973 .